At present, MGT-based blood group test card has been used extensively in the field of blood typing, and MGT boasts of easy operation, high sensitivity, accurate results that can be saved and other strengthens, which allowed it to become method recommended by American Association of Blood Banks (AABB), technique recognized by FDA and internationally recognized blood group analysis test technique.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

According to IQVIA statistics, the global IVD market expanded 6% LC in 2023, continuing to show a rebound from the COVID period.

Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2025.

Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 28, 2025.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will invest USD 50 billion into the United States of America in the next five years. These investments further strengthen Roche’s already significant US footprint with 13 manufacturing and 15 R&D sites across the Pharmaceutical and Diagnostics Divisions, and are expected to create more than 12,000 new jobs, including nearly 6,500 construction jobs, as well as 1,000 jobs at new and expanded facilities.

China's healthcare sector is making steady progress in opening up to foreign investment and expertise, with more than 150 joint-venture and wholly overseas-invested medical institutions now operating nationwide, a senior health official announced Monday.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and North Mississippi Health Services announced today that Labcorp has completed its acquisition of North Mississippi Health Services’ ambulatory outreach laboratory business and become a referral laboratory for its seven hospitals and clinic laboratories.

The 2024 annual reports of major Chinese IVD companies released.

The Trump administration's fiscal-year 2026 budget proposal calls for a roughly 40 percent cut in funding for the National Institutes of Health.

Diasorin (FTSE MIB: DIA) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the second1 of its 3 multiplex molecular panels for blood culture pathogen identification on the LIAISON PLEX® system.

BioMérieux's year-over-year sales grew approximately 14 percent for the first quarter, the firm reported on Thursday, prompting it to confirm its previous full-year revenue guidance.